Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

• Status: Completed
• Trial end date: 2009-06-10
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant.

PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fred Hutchinson Cancer Research Center
• Treatments: Ondansetron

Criteria

Inclusion

• Autologous PBSC transplant patient

• English-speaking

• Planned cryopreserved PBSC infusion at the SCCA outpatient clinic

Exclusion

• History of prior autologous transplant

• Non-English-speaking

• Planned cryopreserved PBSC infusion at the UWMC inpatient unit

• Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion

• Allergy or adverse reaction to ondansetron